Articles tagged "Efficacy"

2022 American Transplant Congress
Safety and Efficacy of Peri-Vaccination Antimetabolite Hold to Augment Third SARS-CoV-2 Vaccine Dose Response in Lung Transplant Recipients
S. Frey, J. Ruck, J. Alejo, L. Barker, W. Werbel, R. Avery, D. Segev, P. Shah
Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: Lung transplant recipients (LTRs) are less likely than other solid organ transplant recipients (SOTRs) to develop an antibody response to SARS-CoV-2 vaccination. Mycophenolate has…
2022 American Transplant Congress
Poor Tolerability of CFTR Modulator Therapy in Lung Transplant Recipients
C. Doligalski, C. McKinzie, A. Yang, R. Coakley
UNC Health, Chapel Hill, NC
*Purpose: Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is a highly effective therapy for cystic fibrosis (CF) with potential benefits in lung transplant recipients (LTRs) for extrapulmonary CF manifestations, however…
2022 American Transplant Congress
Evaluation of Conversion from Immediate Release (IR) Tacrolimus to LCP-Tacrolimus (Envarsus XR®, LCP) in Heart Transplant Recipients
E. Foster¹, A. Iaria¹, J. Negrelli², M. Fine², M. Yu², M. Liebo²
¹University of Illinois at Chicago, Chicago, IL, ²Loyola University Medical Center, Maywood, IL
*Purpose: The purpose of this study was to assess outcomes in heart transplant recipients who were converted from IR tacrolimus to LCPT. Limited data exists…
2022 American Transplant Congress
Noroviral Diarrhea in Solid Organ Transplant Recipients: Characteristics, Interventions and Outcomes
S. N. Nair, A. Bhaskaran, A. Chandorkar, L. Fontana, K. Obeid
University of Minnesota, Minneapolis, MN
*Purpose: Norovirus may result in significant morbidity in solid organ transplant (SOT) recipients. There is limited evidence for therapeutics beyond supportive care for the management…
2022 American Transplant Congress
Enhanced Delivery of Nanomedicine to Human Kidney During Ex Vivo Perfusion
C. Albert¹, L. Bracaglia¹, A. Koide², J. R. DiRito¹, T. Lysyy¹, E. Christopher¹, J. Grundler¹, J. T. Langford¹, D. Haakinson¹, J. S. Pober¹, W. M. Saltzman¹, S. Koide², G. Tietjen¹
¹Yale University, new haven, CT, ²Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY
*Purpose: An efficient delivery of therapeutic agents to graft endothelial cells (ECs) prior to transplantation could render organs more resistant to injury, improving clinical outcomes…
2021 American Transplant Congress
Automated Electronic Donor Referrals Have Increased Transplantation
J. Piano
Transplant Connect, Santa Monica, CA
*Purpose: It is well understood and supported by previous studies that costly inefficiencies exist in the current phone-based process by which hospitals refer potential donors…
2021 American Transplant Congress
Efficacy of MAU868, a Novel BKV Neutralizing Monoclonal Antibody (mAb), for the Treatment of Severe BK Virus Nephropathy (BKVN) After Kidney Transplant
S. C. Jordan¹, N. Ammerman², M. Toyoda³, K. Lim², J. R. Abend⁴, A. Patick⁵, M. R. Hodges⁵, A. Vo², S. J. Kovacs⁶
¹Comprehensive Transplant Center, Cedars Sinai Medical Ctr, West Hollywood, CA, ²Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, ³Cedars Sinai Medical Ctr, Los Angeles, CA, ⁴Novartis Institutes for BioMedical Research, Virology Research, Emeryville, CA, ⁵Amplyx Pharmaceuticals, San Diego, CA, ⁶Novartis Institutes for BioMedical Research, Translational Medicine, East Hanover, NJ
*Purpose: BKV reactivation leading to nephropathy and allograft loss in kidney transplant (KT) recipients remains a clinical significant concern. No specific or effective anti-BKV therapies…
2021 American Transplant Congress
Successful Prophylaxis of Antibody-Mediated Rejection by Downregulation of C5 Expression via RNA Interference in a Rat Kidney Transplant Model
H. Ishigooka¹, S. Motoi², T. Yamakawa¹, C. Matsui², Y. Suzuki³, R. Ishii¹, K. Saiga¹, D. Tokita¹, T. Imai², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²KAN Research Institute, Inc., Kobe, Japan, ³Tsukuba Research Laboratories, Eisai, Co., Ltd., Ibaraki, Japan
*Purpose: Antibody-mediated rejection (AMR) is a major contributor towards poor prognosis in kidney transplantation. Circulating donor-specific antibodies (DSAs) cause AMR with complement activation. This study…
2021 American Transplant Congress
Versatile Strategy to Enhance Nanomedicine Delivery to Graft Endothelial Cells
C. Albert¹, L. G. Bracaglia¹, A. Koide², J. DiRito¹, T. Lysyy¹, C. Edwards¹, J. T. Langford¹, D. Haakinson¹, S. A. Hosgood³, M. L. Nicholson³, J. S. Pober¹, W. M. Saltzman¹, S. Kiode², G. Tietjen¹
¹Yale University, new haven, CT, ²Perlmutter Cancer Center, New York University, Langone Medical Center, New York, NY, ³University of Cambridge, Cambridge, United Kingdom
*Purpose: Efficient delivery of therapeutics to graft endothelial cells (EC) can potentially render organs more resistant to injury, improving clinical outcomes. Specific targeting of polymeric…
2021 American Transplant Congress
Utilizing Risk Factors to Guide Prevention of Invasive Fungal Infections in Liver Transplant Recipients
K. Fitton, A. Chan, C. Truax, B. Sirandas, T. Larson, L. Smith, A. Carlson
University of Utah Health, Salt Lake City, UT
*Purpose: Invasive fungal infection (IFI) after liver transplant (LT) is associated with significant morbidity and mortality. The optimal antifungal prophylaxis regimen has not been defined.…